Tags

Type your tag names separated by a space and hit enter

Ceftolozane-tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing healthcare-associated infections in Australia and New Zealand: Report from an Antimicrobial Surveillance Program (2013-2015).
J Glob Antimicrob Resist. 2017 09; 10:186-194.JG

Abstract

OBJECTIVES

To evaluate the in vitro activity of ceftolozane-tazobactam and comparator agents tested against isolates of Enterobacteriaceae and Pseudomonas aeruginosa from patients in Australia and New Zealand with healthcare-associated infection.

METHODS

A total of 1459 gram-negative organisms (440 P. aeruginosa and 1019 Enterobacteriaceae) were consecutively collected from 11 medical centers located in Australia and New Zealand. The organisms were tested for susceptibility by broth microdilution methods as described by the CLSI M07-A10 document and the results interpreted according to EUCAST and CLSI breakpoint criteria.

RESULTS

Ceftolozane-tazobactam (MIC50/90, 0.25/0.5μg/mL; 97.7/95.9% susceptible [CLSI/EUCAST]), meropenem (MIC50/90, ≤0.06/≤0.06μg/mL; 99.8/99.9% susceptible [CLSI/EUCAST]) and amikacin (MIC50/90, 2/4μg/mL; 99.8/99.6% susceptible [CLSI/EUCAST]) were the most active compounds tested against Enterobacteriaceae. Enterobacteriaceae isolates displayed susceptibility rates to other β-lactam agents ranging from 95.3/94.4% for cefepime, 94.1/91.4% for piperacillin-tazobactam, and 93.3/91.5% for ceftazidime using CLSI/EUCAST breakpoints. Among the Enterobacteriaceae isolates tested, 0.1% were CRE and 6.6% exhibited an ESBL non-CRE phenotype. Whereas ceftolozane-tazobactam showed good activity against ESBL non-CRE phenotype strains of Enterobacteriaceae (MIC50/90, 0.5/2μg/mL), it lacked useful activity (MIC, >32μg/mL) against the single isolate with a CRE resistant phenotype. Ceftolozane-tazobactam was the most potent (MIC50/90, 0.5/2μg/mL) β-lactam agent tested against P. aeruginosa isolates, inhibiting 95.7% at an MIC of ≤4μg/mL.

CONCLUSIONS

Ceftolozane-tazobactam was the most active β-lactam agent tested against P. aeruginosa and demonstrated higher in vitro activity than currently available cephalosporins and piperacillin-tazobactam when tested against Enterobacteriaceae.

Authors+Show Affiliations

JMI Laboratories, North Liberty, IA, USA; University of Iowa College of Medicine, Iowa City, IA, USA.JMI Laboratories, North Liberty, IA, USA. Electronic address: dee-shortridge@jmilabs.com.JMI Laboratories, North Liberty, IA, USA.JMI Laboratories, North Liberty, IA, USA.JMI Laboratories, North Liberty, IA, USA.

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

28735046

Citation

Pfaller, M A., et al. "Ceftolozane-tazobactam Activity Against Drug-resistant Enterobacteriaceae and Pseudomonas Aeruginosa Causing Healthcare-associated Infections in Australia and New Zealand: Report From an Antimicrobial Surveillance Program (2013-2015)." Journal of Global Antimicrobial Resistance, vol. 10, 2017, pp. 186-194.
Pfaller MA, Shortridge D, Sader HS, et al. Ceftolozane-tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing healthcare-associated infections in Australia and New Zealand: Report from an Antimicrobial Surveillance Program (2013-2015). J Glob Antimicrob Resist. 2017;10:186-194.
Pfaller, M. A., Shortridge, D., Sader, H. S., Flamm, R. K., & Castanheira, M. (2017). Ceftolozane-tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing healthcare-associated infections in Australia and New Zealand: Report from an Antimicrobial Surveillance Program (2013-2015). Journal of Global Antimicrobial Resistance, 10, 186-194. https://doi.org/10.1016/j.jgar.2017.05.025
Pfaller MA, et al. Ceftolozane-tazobactam Activity Against Drug-resistant Enterobacteriaceae and Pseudomonas Aeruginosa Causing Healthcare-associated Infections in Australia and New Zealand: Report From an Antimicrobial Surveillance Program (2013-2015). J Glob Antimicrob Resist. 2017;10:186-194. PubMed PMID: 28735046.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Ceftolozane-tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing healthcare-associated infections in Australia and New Zealand: Report from an Antimicrobial Surveillance Program (2013-2015). AU - Pfaller,M A, AU - Shortridge,D, AU - Sader,H S, AU - Flamm,R K, AU - Castanheira,M, Y1 - 2017/07/19/ PY - 2017/05/03/received PY - 2017/05/30/revised PY - 2017/05/31/accepted PY - 2017/7/25/pubmed PY - 2019/5/14/medline PY - 2017/7/24/entrez KW - Australia KW - Ceftolozane–tazobactam KW - Drug resistance KW - Enterobacteriaceae KW - New Zealand KW - P. aeruginosa KW - Surveillance SP - 186 EP - 194 JF - Journal of global antimicrobial resistance JO - J Glob Antimicrob Resist VL - 10 N2 - OBJECTIVES: To evaluate the in vitro activity of ceftolozane-tazobactam and comparator agents tested against isolates of Enterobacteriaceae and Pseudomonas aeruginosa from patients in Australia and New Zealand with healthcare-associated infection. METHODS: A total of 1459 gram-negative organisms (440 P. aeruginosa and 1019 Enterobacteriaceae) were consecutively collected from 11 medical centers located in Australia and New Zealand. The organisms were tested for susceptibility by broth microdilution methods as described by the CLSI M07-A10 document and the results interpreted according to EUCAST and CLSI breakpoint criteria. RESULTS: Ceftolozane-tazobactam (MIC50/90, 0.25/0.5μg/mL; 97.7/95.9% susceptible [CLSI/EUCAST]), meropenem (MIC50/90, ≤0.06/≤0.06μg/mL; 99.8/99.9% susceptible [CLSI/EUCAST]) and amikacin (MIC50/90, 2/4μg/mL; 99.8/99.6% susceptible [CLSI/EUCAST]) were the most active compounds tested against Enterobacteriaceae. Enterobacteriaceae isolates displayed susceptibility rates to other β-lactam agents ranging from 95.3/94.4% for cefepime, 94.1/91.4% for piperacillin-tazobactam, and 93.3/91.5% for ceftazidime using CLSI/EUCAST breakpoints. Among the Enterobacteriaceae isolates tested, 0.1% were CRE and 6.6% exhibited an ESBL non-CRE phenotype. Whereas ceftolozane-tazobactam showed good activity against ESBL non-CRE phenotype strains of Enterobacteriaceae (MIC50/90, 0.5/2μg/mL), it lacked useful activity (MIC, >32μg/mL) against the single isolate with a CRE resistant phenotype. Ceftolozane-tazobactam was the most potent (MIC50/90, 0.5/2μg/mL) β-lactam agent tested against P. aeruginosa isolates, inhibiting 95.7% at an MIC of ≤4μg/mL. CONCLUSIONS: Ceftolozane-tazobactam was the most active β-lactam agent tested against P. aeruginosa and demonstrated higher in vitro activity than currently available cephalosporins and piperacillin-tazobactam when tested against Enterobacteriaceae. SN - 2213-7173 UR - https://www.unboundmedicine.com/medline/citation/28735046/Ceftolozane_tazobactam_activity_against_drug_resistant_Enterobacteriaceae_and_Pseudomonas_aeruginosa_causing_healthcare_associated_infections_in_Australia_and_New_Zealand:_Report_from_an_Antimicrobial_Surveillance_Program__2013_2015__ L2 - https://linkinghub.elsevier.com/retrieve/pii/S2213-7165(17)30113-3 DB - PRIME DP - Unbound Medicine ER -